Video Interview: Cenna Puts Its Own Spin On Trusted Amyloid Beta Target
This article was originally published in Scrip
Amyloid beta is a well-established target in Alzheimer's disease, yet there have been many failures in this development space. Cenna Biosciences founder and CEO Nazneen Dewji explains to "The Pink Sheet" (an affiliate of Scrip) senior writer Emily Hayes why she thinks her company's approach could succeed.
Register for our free email digests: